ClinicalTrials.gg
Active, not recruitingNCT03030495IMPACT-FFRUpdated Nov 19, 2026

Registry of Comprehensive Imaging and Physiological Evaluation of Deferred Lesions Based on FFR

An observational study in Ischemic Heart Disease, sponsored by Samsung Medical Center. Active, not recruiting at 4 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Samsung Medical Center · Observational

How we know

Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Myocardial Ischemia by Samsung Medical Center — 3 open to participants now, 6 under way, none of them phase 3. Myocardial Ischemia · Samsung Medical Center.

Planned enrollment
2nd of 10
1,400 · median 902
Started
2016
with 3 others
Observational
10 of 13
1 open now
Registered
3rd of 13
by date

Among the 13 studies in Myocardial Ischemia by Samsung Medical Center, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2016, is one of 10 observational ones, and was the 3rd registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

3 of the 13 studies in Myocardial Ischemia by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Myocardial Ischemia by Samsung Medical Center, or all of them as a file.
02

Study summary

  1. To compare the risk of atherosclerotic lesion progression and subsequent patient-oriented composite outcomes (all-cause mortality, any MI, or any Ischemia-driven repeat revascularization) between deferred lesions with or without over microvascular disease, defined as physiological classification
  2. To explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment
Read the detailed description

The coronary artery system has 3 components with different functions: conductive epicardial coronary arteries, arterioles, and capillaries. When any one of these systems fails, myocardial ischemia can occur. Therefore, the presence of epicardial coronary artery stenosis is not necessarily a prerequisite for ischemic heart disease (IHD). Although it has not been established that microvascular disease is independent of macrovascular disease, clinical studies have consistently shown that the presence of microvascular disease is an independent predictor of poor clinical outcomes, especially in patients with acute myocardial infarction (MI).

The pressure-derived fractional flow reserve (FFR) index has become a standard invasive method to evaluate the functional significance of epicardial coronary artery stenosis, and clinical outcomes of FFR-guided percutaneous coronary intervention (PCI) have proven to be better than those of angiography-guided PCI or medical treatment. Although FFR-guided PCI has been reported to improve patient outcomes and FFR is now regarded as the gold-standard invasive method to assess the functional significance of coronary artery stenosis, there is still room for further improvement in the diagnosis and treatment of patients with high FFR. In the FAME II study, 14.6% of the registry arm (FFR > 0.80 and deferral of PCI) experienced persistent angina, and 9.0% of these patients had clinical events during a 2-year follow-up period.

Therefore, microvascular assessment using coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR) can provide additional diagnostic and prognostic insights for IHD patients, especially in those with high FFR.

Recently, Lee et al. (JACC 2016) investigated clinical outcomes among patients with high-FFR and deferred revascularization, according to physiologic classification using CFR and IMR. Lee et al. firstly presented that 7.0% of patients with high FFR had high IMR and low CFR and were regarded as having overt microvascular disease. Although the proportion of patients with high FFR who had overt microvascular disease was small, Group D had the poorest clinical outcomes during follow-up. The presence of overt microvascular disease was an independent prognostic factor in patients with high FFR. In addition, the presence of overt microvascular disease had additive prognostic value aside from clinical risk factors, with significantly improved discriminant function of the prediction model. These results suggest that the invasive physiologic assessment for microvascular disease combined with CFR and IMR can help identify patients at high risk for future cardiovascular events among those with high FFR.

Previous studies have shown that the presence of microvascular disease is associated with a higher risk of cardiovascular events such as cardiac death, MI, or revascularization in patients without flow-limiting epicardial stenosis. Several mechanisms have been proposed for the association of microvascular disease and poor clinical outcomes. In addition to myocardial ischemia, microvascular disease is reported to be associated with endothelial dysfunction and inflammatory activity that precedes intimal thickening, lipid deposition in the macrovascular system, and coronary vasomotor dysfunction. In a study by Dhawan et al., coronary microvascular dysfunction in patients with non-obstructive coronary artery disease was associated with higher serum high-sensitivity C-reactive protein and a higher frequency of thin-cap fibroatheroma.

In the Lee et al.'s study, the higher clinical event rates in patients with overt microvascular disease resulted from cardiac death and revascularization rates higher than those of the other groups. These results imply that the presence of overt microvascular disease can induce accentuated atherosclerotic progression and subsequent clinical events including cardiac death and ischemia-driven repeat revascularization.

Therefore, the IMaging and Physiologic Predictors of Atherosclerotic Progression in Deferred Lesions with Contemporary Medical Treatment based on Fractional Flow Reserve-guided Strategy (IMPACT-FFR registry) was designed to compare the risk of atherosclerotic plaque progression and subsequent clinical events between deferred lesions with or without over microvascular disease, defined as physiological classification and also to explore independent predictors of atherosclerotic lesion progression in deferred lesions based on fractional flow reserve-guided strategy and treated by contemporary medical treatment.

03

Conditions studied

  • Ischemic Heart Disease

Keywords

  • Ischemic Heart Disease
  • Stable angina
  • Fractional flow reserve
  • Index of Microcirculatory Resistance
  • Coronary Flow Reserve
  • Intravascular Imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with intermediate degree of stenosis (30-70% stenosis by visual estimation) with fractional flow reserve of >0.80 in major epicardial coronary artery amenable to stent implantation or vessel size ≥2.5 mm.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be ≥ 18 years
  • Patients suspected with ischemic heart disease
  • Patients with intermediate degree of stenosis (30-70% stenosis by visual estimation) with fractional flow reserve of >0.80 in major epicardial coronary artery amenable to stent implantation or vessel size≥2.5 mm
  • Patients whose coronary stenosis were evaluated by invasive imaging techniques (intravascular ultrasound and optical coherence tomography) and physiologic assessment (coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve)
  • Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and he/she or his/her legally authorized representative provides written to any study related procedure

Exclusion criteria

Exclusion Criteria:

  • End-staged renal disease on peritoneal dialysis or hemodialysis (estimated \< 15mL/min)
  • Acute hepatic injury
  • Cardiogenic shock (systolic blood pressure \< 90mmHg or requiring inotropics to maintain blood pressure > 90mmHg)
  • The patient has a known or to any of the following medications: statin, ezetimibe, heparin, aspirin, clopidogrel, prasugrel, ticagrelor
  • Non-cardiac co-morbid conditions are present with \<2 year (per site investigator's medical judgment)
  • Unable to perform invasive imaging study (intravascular ultrasound and optical coherence tomography) or physiologic assessment (coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,400 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Overt microvascular disease

    Fractional flow reserve\>0.80, coronary flow reserve\<2 \& Index of microvascular resistance\>25U

    Device: Comprehensive physiologic evaluation · Device: Intravascular imaging devices

  • No Overt microvascular disease

    Fractional flow reserve\>0.80, coronary flow reserve\>2 \& Index of microvascular resistance\<25U

    Device: Comprehensive physiologic evaluation · Device: Intravascular imaging devices

Interventions

  • DeviceComprehensive physiologic evaluation

    Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance

    Also known as: Comprehensive physiologic evaluation using pressure-temperature sensor wire

  • DeviceIntravascular imaging devices

    Intravascular ultrasound or optical coherence tomography

    Also known as: Intravascular ultrasound or optical coherence tomography

06

What researchers measure

Primary outcomes

  1. patient-oriented composite outcome

    a composite of all-cause death, MI, any repeat revascularization

    Time frame: 24 months

Secondary outcomes

  1. patient-oriented composite outcome

    a composite of all-cause death, MI, any repeat revascularization

    Time frame: 12 months

  2. patient-oriented composite outcome

    a composite of all-cause death, MI, any repeat revascularization

    Time frame: 60 months

  3. All-cause death

    All-cause death

    Time frame: 24 months

  4. cardiac death

    cardiac death

    Time frame: 24 months

  5. Target-vessel nonfatal MI

    Target-vessel nonfatal MI

    Time frame: 24 months

  6. Non-target vessel nonfatal MI

    Non-target vessel nonfatal MI

    Time frame: 24 months

  7. All-cause nonfatal MI

    All-cause nonfatal MI

    Time frame: 24 months

  8. Seattle Angina Questionnaires

    Angina severity measured with Seattle Angina Questionnaires

    Time frame: 24 months

  9. Change in normalized total atheroma volume

    TAVnormalized = \[Σ (EEM CSA - lumen CSA) / no. of images in pullback images in cohort\] X median no. of images in cohort

    Time frame: 12 months

  10. Change in total atheroma volume index

    Indexed total atheroma volume (TAVi): Σ(EEM CSA -lumen CSA)/plaque length

    Time frame: 12 months

  11. Change in fibrous cap thickness by OCT

    Change in fibrous cap thickness by OCT at 12-month

    Time frame: 12 months

  12. Change in Plaque burden at minimum lumen area site

    Change in Plaque burden at minimum lumen area site at 12-month Plaque burden = (EEM-MLA)/EEM x 100

    Time frame: 12 months

  13. Change in Fractional flow reserve

    Change in Fractional flow reserve at 12-month

    Time frame: 12 months

  14. Change in coronary flow reserve

    Change in coronary flow reserve at 12-month

    Time frame: 12 months

  15. Change in index of microcirculatory resistance

    Change in index of microcirculatory resistance at 12-month

    Time frame: 12 months

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: Yes — After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2016 (actual). Primary completion is estimated for Dec 2026, 120 months after the start.

Of 165 non-industry observational studies under Myocardial Ischemia, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 127. This study's planned 120 months is above that.

Counting every sponsor, half of 204 studies reached it within 40 months; a quarter within 21 and three quarters within 90.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2016
First posted
Jan 25, 2017
StartActual
Dec 1, 2016
Primary completionEst.
Dec 31, 2026was Dec 2025
CompletionEst.
Dec 31, 2026was Dec 2025
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Dec 31, 2026
Nov 19, 2026
Study completion
Dec 31, 2025→Dec 31, 2026
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Dec 31, 2025→Dec 31, 2026
    Study completion Dec 31, 2025→Dec 31, 2026
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03030495
Collaborators
Seoul National University Hospital, Inje University Ilsan Paik Hospital, Ulsan University Hospital, Keimyung University Dongsan Medical Center
Responsible party
Joo-Yong Hahn (Professor, Samsung Medical Center) — Principal investigator
First posted
Jan 25, 2017
Start date
Dec 1, 2016
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 19, 2026

Study contacts

Joo-Yong Hahn, MD, PhD
study chair · Samsung Medical Center
Bon-Kwon Koo, MD, PhD
study chair · Seoul National University Hospital
Joo-Yong Hahn, MD, PhD
principal investigator · Samsung Medical Center
Joo Myung Lee, MD, MPH, PhD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion